CONFERENCE CONTENT

MEDICAL EDUCATIONAL COMPONENT

Clinical Questions for Common Lymphomas
- Lymphoma Research Foundation Presentation – T-Cell Lymphoma
- Localized DLBCL – What Are The Current Treatment Options?
- Controversy: Should Subtypes of Advanced Stage DLBCL Be Treated Differently?
- Controversy: Localized Hodgkin Lymphoma – Should Any Patient Receive Radiation Therapy?
- Should PET Scanning Be Used to Direct Therapy for Advanced Hodgkin Lymphoma?
- How Should We Treat Lymphocyte Predominant Hodgkin Lymphoma?
- Controversy: Is Follicular Lymphoma a Curable Lymphoma?
- Is Watch-and-Wait Still Appropriate for Some Patients with Follicular Lymphoma?
- Transplantation for Follicular Lymphoma – Does It Still Have a Role?
- Update on NCCN Guidelines for NHL – How Are The Guidelines Used?

Clinical Case Conference
- Should FL1/2 Be Treated Differently Than FL3?
- How Should We Treat Hodgkin Lymphoma That Is CD20 Positive?

Clinical Questions and New Drugs for Uncommon Lymphomas
- Mantle Cell Lymphoma – What Is The Current Standard of Care for Older and Younger Patients?
- What Are The Newer Agents That Have Clinical Activity in MCL?
- Chronic Lymphocytic Leukemia - Current Standard of Care for High Risk Patients?
- Novel Agents with Activity in CLL/SLL
- CNS and Leptomeningeal Lymphomas – Update on Treatment Options
- Lymphomatoid Granulomatosis
- T-cell Lymphoma – Overview of WHO Classification
- PTCL – Use of Aggressive Regimens and Stem Cell Transplantation – What Subtypes Benefit?
- PTCL – Update on Novel Therapies
- The Spectrum of Cutaneous T-cell Lymphomas – Standard and Novel therapies

Clinical Case Conference
- How Should We Treat DLBCL in Older Patients?
- Treatment for Patients with Indolent Lymphoma Other Than Follicular

Rare Types of Lymphoma and Novel Agents for Lymphoma
- Novel agents for targeting the B-cell Receptor, signal transduction and kinase Pathways
- Agents targeting the stromal elements of the lymph node
- Inducing apoptosis in lymphoma cells through novel agents
- Monoclonal antibodies other than CD20 for NHL and HL.
- Other CD20 monoclonal antibodies – comparison to rituximab
- Translational Research in Lymphoma: Where Do We Stand?
- Current therapy options for extranodal marginal zone lymphoma
- Update on current therapy for lymphoblastic non-Hodgkin lymphoma
- What is the best therapy for Burkitt lymphoma or “double hit” lymphoma?

NURSING EDUCATIONAL COMPONENT

- Young Adult Survivor (Lymphoma Research Foundation)
- Case Studies: Mantle Cell Lymphoma
- Classification and Treatment of T-Cell Lymphoma
- Novel Therapies: Pharmacogenomics and Response Adaptive Therapy
- CLL vs SLL: Diagnosis and Treatment
- CNS Lymphoma
- Radiation Oncology: Recent Advances
- Case Studies: Implementing the Role of the Nurse Navigator
- Infection Issues in Lymphoma
- Recent Advances in Transplantation for Lymphoma

PATHOLOGY EDUCATIONAL COMPONENT

- Epidemiology of NHL Around the World
- Peripheral T-cell Lymphomas
- Primary Splenic B-Cell Lymphomas
- Hodgkin Lymphomas
- Follicular Lymphomas